NCT03675451View on ClinicalTrials.gov

PSMA Imaging of Localized Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

June 27, 2018

Study Completion Date

June 27, 2018

Conditions
Prostate Cancer
Interventions
DRUG

89ZR-DF-IAB2M

injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan

DRUG

68Ga-PSMA-HBED-CC

Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.

Trial Locations (1)

10065

Weill Cornell Medicine, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT03675451 - PSMA Imaging of Localized Prostate Cancer | Biotech Hunter | Biotech Hunter